Tag : Sorafenib

Latest News

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.

Newsemia
Kelley, RK; Ryoo, B-Y; Merle, P; Park, J-W; Bolondi, L; Chan, SL; Lim, HY; … Abou-Alfa, GK; + view all Kelley, RK; Ryoo, B-Y; Merle,...
Pharma / Biotech

Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.

Newsemia
Related Articles Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Oncologist. 2020 Jun 16;: Authors: Harding JJ, Kelley...
Pharma / Biotech

Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake.

Newsemia
Related Articles Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake. Pharmacogenomics. 2020 Feb;21(3):173-179 Authors: Ba HL, Mbatchi L, Gattacceca F,...
Latest News

Scientists discover potential drug compounds that target common type of liver cancer

Newsemia
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore, and the Agency for Science, Technology and Research (A*STAR)’s Genome Institute...
Gastroenterology

Combination therapy improves survival in patients with hepatocellular carcinoma

Newsemia
Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma...
Gastroenterology

Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment

Newsemia
Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment Source link...
Gastroenterology

Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma

Newsemia
Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma Source link...
Gastroenterology

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Newsemia
Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets. Source link...
Gastroenterology

Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Newsemia
Transarterial chemoembolization (TACE) is the recommended treatment for hepatocellular carcinoma (HCC) patients at Barcelona Clinic Liver Cancer (BCLC) B-stage, whereas sorafenib is an orally administered...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy